Evidence map›Paper›PMID 35044839›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.

Elisa Pasqual, Sara Schonfeld, Lindsay M Morton, Daphnée Villoing, Choonsik Lee, Amy Berrington de Gonzalez, Cari M Kitahara

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Elisa PasqualDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.ORCID 0000-0001-7181-6160
Sara SchonfeldDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.ORCID 0000-0002-4368-4647
Lindsay M MortonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.ORCID 0000-0001-9767-2310
Daphnée VilloingInstitut de Cancérologie de l'Ouest, Saint-Herblain, France.ORCID 0000-0003-1437-2211
Choonsik LeeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.ORCID 0000-0002-6219-6622
Amy Berrington de GonzalezDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.ORCID 0000-0002-7332-8387
Cari M KitaharaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.ORCID 0000-0001-6416-4432
National Cancer Institute · USInstitut de Cancérologie de l'Ouest · FR

Funding

Studies of Populations Exposed to Therapeutic Medical Radiation and Other AgentsZIACP010131 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$81.0M
6 · The paper itself

Abstract

purposeSince the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment increased markedly. RAI has been associated with an increased risk of leukemia, but risks of second solid malignancies remain unclear. We aimed to quantify risks of second malignancies associated with RAI treatment for DTC in children and young adults, who are more susceptible than older adults to the late effects of radiation.

methodsUsing nine US SEER cancer registries (1975-2017), we estimated relative risks (RRs) for solid and hematologic malignancies associated with RAI (yes

resultsAmong 27,050 ≥ 5-year survivors (median follow-up = 15 years), RAI treatment (45%) was associated with increased risk of solid malignancies (RR = 1.23; 95% CI, 1.11 to 1.37). Risks were increased for uterine cancer (RR = 1.55; 95% CI, 1.03 to 2.32) and nonsignificantly for cancers of the salivary gland (RR = 2.15; 95% CI, 0.91 to 5.08), stomach (RR = 1.61; 95% CI, 0.70 to 3.69), lung (RR = 1.42; 95% CI, 0.97 to 2.08), and female breast (RR = 1.18; 95% CI, 0.99 to 1.40). Risks of total solid and female breast cancer, the most common cancer type, were highest among ≥ 20-year DTC survivors (RR

conclusionIn addition to leukemia, RAI treatment for childhood and young-adulthood DTC was associated with increased risks of several solid cancers, particularly more than 20 years after exposure, supporting the need for long-term surveillance of these patients.

Indexed as

AdenocarcinomaHematologic NeoplasmsLeukemiaNeoplasms, Radiation-InducedNeoplasms, Second PrimaryThyroid NeoplasmsAdultAgedChildFemaleHumansIodine RadioisotopesMiddle AgedYoung AdultIodine Radioisotopes

Identifiers

PMID35044839
PMCPMC9061144
OpenAlexW4206830728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.